{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:39:03Z","timestamp":1791085143229,"version":"4.1.0"},"reference-count":41,"publisher":"Korean Association for the Study of Intestinal Diseases","issue":"3","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Eisai Co., Ltd"}],"content-domain":{"domain":["irjournal.org"],"crossmark-restriction":true},"short-container-title":["Intest Res"],"published-print":{"date-parts":[[2021,7,30]]},"abstract":"<jats:p>Background\/Aims: The safety and effectiveness of adalimumab was demonstrated in a phase 3 trial in Japanese patients with intestinal Beh\u00e7et\u2019s disease. The aim of this study was to evaluate the long-term safety and effectiveness of adalimumab in Japanese patients with intestinal Beh\u00e7et\u2019s disease.Methods: This prospective, all-case, post-marketing study was conducted at 254 centers in Japanese patients with intestinal Beh\u00e7et\u2019s disease receiving adalimumab. The primary endpoint was incidence of adverse drug reactions. Effectiveness endpoints included global improvement rating and change in C-reactive protein levels.Results: Of the 473 registered patients, 462 and 383 included in the safety and effectiveness populations were administered adalimumab for a mean of 515.3 and 579.5 days, respectively. Overall, 395 patients (85.5%) received adalimumab at the recommended dose. Adverse drug reactions and serious adverse drug reactions were reported in 120 (25.97%) and 51 (11.04%) patients, respectively. The incidence of adverse drug reactions was significantly higher in patients with comorbidities (P&lt; 0.0001), patients taking concomitant oral corticosteroids (P&lt; 0.0001), and those not self-administering adalimumab (P= 0.0257). At study end, global improvement rating was \u201ceffective\u201d (n = 156, 40.7%) or \u201cmarkedly effective\u201d (n = 168, 43.9%) in 324 patients (overall effective, 84.6%). Mean C-reactive protein levels (mg\/dL) decreased from 1.96 at baseline (n = 324) to 0.58 at week 24 (n = 208) and 0.25 at week 156 (n = 37).Conclusions: This large real-world study confirmed the long-term safety and effectiveness of adalimumab in patients with intestinal Beh\u00e7et\u2019s disease. No new safety concerns were identified. (Clinical trial registration number: NCT01960790)<\/jats:p>","DOI":"10.5217\/ir.2020.00013","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T08:51:17Z","timestamp":1597913477000},"page":"301-312","update-policy":"https:\/\/doi.org\/10.5217\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Beh\u00e7et\u2019s disease: results from a large real-world observational study"],"prefix":"10.5217","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-9793","authenticated-orcid":true,"given":"Yasuo","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1569-1540","authenticated-orcid":true,"given":"Takashi","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1345-2685","authenticated-orcid":true,"given":"Mariko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2986-2280","authenticated-orcid":true,"given":"Kazuo","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0850-767X","authenticated-orcid":true,"given":"Tomoyo","family":"Shimamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6256-1204","authenticated-orcid":true,"given":"Toshifumi","family":"Hibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3168","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-20"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910213411707"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.124875"},{"key":"ref4","volume-title":"","author":"Matsuda","year":"2002"},{"key":"ref5","volume-title":""},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2017.15.3.395"},{"key":"ref7","first-page":"658","volume-title":"Beh\u00e7et\u2019s disease in Saudi Arabia","author":"al-Dalaan","year":"1994"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.1997.38.6.411"},{"key":"ref9","first-page":"207","volume-title":"Clinical characteristics of Beh\u00e7et\u2019s disease in southern Taiwan","author":"Chen","year":"2001"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-1127-9"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.107636"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.08.042"},{"key":"ref13","first-page":"1279","volume-title":"","author":"Kastner","year":"1997"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(79)90004-0"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e318211bf28"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-013-0872-4"},{"key":"ref17","first-page":"165","volume-title":"","author":"Cheon","year":"2010"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2217\/imt.13.66"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000125"},{"key":"ref20","first-page":"e116","volume-title":"Response rates to medical treatments and long-term clinical outcomes of nonsurgical patients with intestinal Beh\u00e7et disease","author":"Chung","year":"2010"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2017.15.3.318"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2001.02510.x"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s005350200139"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.42.696"},{"key":"ref25","first-page":"S698","volume-title":"Long-term clinical outcomes after the first course of corticosteroid therapy in patients with moderate to severe intestinal Behget\u2019s disease","author":"Park","year":"2010"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw060"},{"key":"ref27","volume-title":""},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2013.54.5.1084"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209322"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.043166"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20956"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04717.x"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.03.002"},{"key":"ref34","first-page":"1078","volume-title":"International Study Group for Beh\u00e7et\u2019s Disease","year":"1990"},{"key":"ref35","first-page":"1654","volume-title":"Patients\u2019 assessment of adalimumab self-injection for Crohn\u2019s disease: a multicenter questionnaire survey (The PEARL Survey)","author":"Hirai","year":"2014"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr2477w"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2010.483314"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3480-x"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes130"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21663"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0678-0"}],"container-title":["Intestinal Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/irjournal.org\/upload\/pdf\/ir-2020-00013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/irjournal.org\/journal\/view.php?doi=10.5217\/ir.2020.00013","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/irjournal.org\/upload\/pdf\/ir-2020-00013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:11:15Z","timestamp":1627258275000},"score":1,"resource":{"primary":{"URL":"http:\/\/irjournal.org\/journal\/view.php?doi=10.5217\/ir.2020.00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,30]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"URL":"https:\/\/doi.org\/10.5217\/ir.2020.00013","relation":{},"ISSN":["1598-9100","2288-1956"],"issn-type":[{"value":"1598-9100","type":"print"},{"value":"2288-1956","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,30]]},"assertion":[{"value":"2020-03-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-20","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-30","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}